Walleye Trading
AMRI

Walleye Trading’s Albany Molecular Research Inc AMRI Stock Holding History

Walleye Trading’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-500
Closed -$9K – 5428
2016
Q4 		$9K Hold
500
– – ﹤0.01% 4352
2016
Q3 		$8K Sell
500
-30,800
-98% -$456K ﹤0.01% 4473
2016
Q2 		$421K Buy
31,300
+22,600
+260% +$330K ﹤0.01% 2361
2016
Q1 		$134K Buy
8,700
+7,300
+521% +$114K ﹤0.01% 3115
2015
Q4 		$28K Sell
1,400
-1,900
-58% -$36.1K ﹤0.01% 4243
2015
Q3 		$57K Sell
3,300
-10,900
-77% -$222K ﹤0.01% 3411
2015
Q2 		$286K Buy
14,200
+5,300
+60% +$102K ﹤0.01% 2161
2015
Q1 		$158K Buy
8,900
+2,100
+31% +$35.8K ﹤0.01% 2375
2014
Q4 		$110K Buy
6,800
+2,600
+62% +$47.7K ﹤0.01% 2740
2014
Q3 		$94K Sell
4,200
-8,700
-67% -$178K ﹤0.01% 2696
2014
Q2 		$260 Buy
12,900
+4,200
+48% +$71.1K ﹤0.01% 1795
2014
Q1 		$162 Buy
+8,700
New +$120K ﹤0.01% 2068

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Walleye Trading's AMRI Position: Q3 2017 in Review

Walleye Trading sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 60,117 shares — an estimated $1.3K sold.

Walleye Trading first reported a position in AMRI in Q4 2013 and held it in 5 quarters. The position peaked at $181K in Q4 2015. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Walleye Trading reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Walleye Trading sold 60,117 Albany Molecular Research Inc shares in Q3 2017, an estimated $1.3K.
  • Walleye Trading first reported a position in Albany Molecular Research Inc in Q4 2013 and held it in 5 quarters.
  • Walleye Trading's Albany Molecular Research Inc position peaked at $181K in Q4 2015.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Walleye Trading's 13F filing for Q3 2017, filed 14 Nov 2017.